Ampel BioSolutions

• NCT03098823

  Phase 4, Completed, 62 people, 4 Apr 2017

• Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study

  Consulting or advice, Fees or honoraria, 28 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov